Form D · Biotechnology

Lumen Bioscience, Inc.

Seattle, WA · CIK 0001703612

Offering snapshot reported Apr 1, 2025 · SEC filing

Reported sold
Yet to sell
Offering amount: $23M
Investors reported
0
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Yet to occur
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Apr 1, 2025InitialYet to sellNo comparison0SEC filing
Nov 19, 2024InitialYet to sellNo comparison0SEC filing
Sep 15, 2023InitialYet to sellNo comparison0SEC filing
Jun 29, 2022InitialYet to sellNo comparison0SEC filing
Nov 12, 2019InitialYet to sellNo comparison0SEC filing

Offering details

Securities
Equity, Option to acquire, Security to be acquired
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-542649

Source: Form D, filed Apr 1, 2025. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Erik Anderson Director
Craig Behnke Executive
Robert Carlson Director
Brian Finrow Director, Executive, Promoter
Mark Litton Director
Marcos Milla Director
John Morrow Executive
Eric Orse Executive
James Roberts Director, Executive, Promoter
Ed Schlect Director
Don Schlosser Executive

Issuer details

Industry: Biotechnology (See others in industry)

Address:
1441 North 34 Th Street, Suite 300
Seattle, WA, 98103